Novartis
NEWS
A look at the lucky drugs that have been hailed a breakthrough by the FDA.
A Novartis drug approved as a second-line treatment for a blood disorder snagged the FDA’s Breakthrough Therapy Designation as a first-line defense.
The company said the Breakthrough Therapy Designation is based on positive results from the Phase III MONALEESA-7 trial.
Ultragenyx CEO Emil Kakkis said the sale of the PRV will provide the company with an “important source of non-dilutive capital” that will be used to advance the company’s pipeline of rare and ultra-rare therapies.
Bruno Strigini, the CEO of Novartis Oncology, plans to exit the company’s Executive Committee by Dec. 31, 2017, and leave entirely in early 2018.
There are hundreds, even thousands of biotech and pharmaceutical companies.
Novartis told Kent Online that the reason the company is looking at closing the facility is the rapid advancements in point of care diagnostic devices.
Speculation has increased that Amazon might enter the pharmacy market after it conducted high-level talks with generic drug companies Mylan and Sandoz, a division of Novartis.
On Wednesday, KBR reported that a male employee at Novartis Korea reported to the company that his female boss sexually harassed him in September.
JOBS
IN THE PRESS